CD19 chimeric antigen receptor T cell therapy for haematological malignancies

British Journal of Haematology

Volumn 169, Issue 4, 2015, Pages 463-478

  Ghorashian, Sara ^a   Pule, Martin ^b,c,d   Amrolia, Persis ^a,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Cellular therapies; Gene transfer; Immunotherapy; T lymphocytes

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; LENTIVIRUS VECTOR; RETROVIRUS VECTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; APLASIA; B LYMPHOCYTE APLASIA; CD4 CD8 RATIO; CELL EXPANSION; CELL SELECTION; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE SYNDROME; ELECTROPORATION; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOTHERAPY; MEMORY T LYMPHOCYTE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SAFETY; T LYMPHOCYTE; TRANSPOSON; TREATMENT RESPONSE; ANIMAL; B LYMPHOCYTE; GENE TRANSFER; GENETICS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; LYMPHOCYTE DEPLETION; PATHOLOGY; PROCEDURES; TRANSPLANTATION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD19; B-LYMPHOCYTES; GENE TRANSFER TECHNIQUES; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOCYTE DEPLETION; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84928413721     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13340     Document Type: Review

References (80)

1. Adusumilli, P.S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D.R. & Sadelain, M. (2014). Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Science Translational Medicine, 6, 261ra151.
2. + T helper cells and hindered by naturally occurring T regulatory cells. Journal of Immunology, 174, 2591-2601.
3. + T cells derived from central memory cells establishes persistent T cell memory in primates. Journal of Clinical Investigation, 118, 294-305.
4. Bollard, C.M., Rossig, C., Calonge, M.J., Huls, M.H., Wagner, H.J., Massague, J., Brenner, M.K., Heslop, H.E. & Rooney, C.M. (2002) Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood, 99, 3179-3187.
5. Bonger, K.M., Chen, L.C., Liu, C.W. & Wandless, T.J. (2011) Small-molecule displacement of a cryptic degron causes conditional protein degradation. Nature Chemical Biology, 7, 531-537.
6. Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C. & Bordignon, C. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, 276, 1719-1724.
7. Brentjens, R.J., Latouche, J.B., Santos, E., Marti, F., Gong, M.C., Lyddane, C., King, P.D., Larson, S., Weiss, M., Riviere, I. & Sadelain, M. (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Medicine, 9, 279-286.
8. Brentjens, R.J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintas-Cardama, A., Larson, S.M. & Sadelain, M. (2007) Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical Cancer Research, 13, 5426-5435.
9. Brentjens, R.J., Riviere, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., Olszewska, M., Bernal, Y., Pegram, H., Przybylowski, M., Hollyman, D., Usachenko, Y., Pirraglia, D., Hosey, J., Santos, E., Halton, E., Maslak, P., Scheinberg, D., Jurcic, J., Heaney, M., Heller, G., Frattini, M. & Sadelain, M. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 118, 4817-4828.
10. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., Borquez-Ojeda, O., Qu, J., Wasielewska, T., He, Q., Bernal, Y., Rijo, I.V., Hedvat, C., Kobos, R., Curran, K., Steinherz, P., Jurcic, J., Rosenblat, T., Maslak, P., Frattini, M. & Sadelain, M. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science Translational Medicine, 5, 177ra38.
11. Burger, J.A. & Gribben, J.G. (2014) The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Seminars in Cancer Biology, 24, 71-81.
12. Carpenito, C., Milone, M.C., Hassan, R., Simonet, J.C., Lakhal, M., Suhoski, M.M., Varela-Rohena, A., Haines, K.M., Heitjan, D.F., Albelda, S.M., Carroll, R.G., Riley, J.L., Pastan, I. & June, C.H. (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the United States of America, 106, 3360-3365.
13. Cheadle, E.J., Hawkins, R.E., Batha, H., O'Neill, A.L., Dovedi, S.J. & Gilham, D.E. (2010) Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. Journal of Immunology, 184, 1885-1896.
14. Chen, Y.Y., Jensen, M.C. & Smolke, C.D. (2010) Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. Proceedings of the National Academy of Sciences of the United States of America, 107, 8531-8536.
15. Christopoulos, P., Pfeifer, D., Bartholome, K., Follo, M., Timmer, J., Fisch, P. & Veelken, H. (2011) Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood, 117, 3836-3846.
16. Cooper, L.J., Topp, M.S., Serrano, L.M., Gonzalez, S., Chang, W.C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S.J. & Jensen, M.C. (2003) T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood, 101, 1637-1644.
17. Cooper, L.J., Al-Kadhimi, Z., Serrano, L.M., Pfeiffer, T., Olivares, S., Castro, A., Chang, W.C., Gonzalez, S., Smith, D., Forman, S.J. & Jensen, M.C. (2005) Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood, 105, 1622-1631.
18. Cruz, C.R., Micklethwaite, K.P., Savoldo, B., Ramos, C.A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A.J., Ito, S., Shpall, E.J., Krance, R.A., Kamble, R.T., Carrum, G., Hosing, C.M., Gee, A.P., Mei, Z., Grilley, B.J., Heslop, H.E., Rooney, C.M., Brenner, M.K., Bollard, C.M. & Dotti, G. (2013) Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood, 122, 2965-2973.
19. Davila, M.L., Kloss, C.C., Gunset, G. & Sadelain, M. (2013) CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS ONE, 8, e61338.
20. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., Qu, J., Wasielewska, T., He, Q., Fink, M., Shinglot, H., Youssif, M., Satter, M., Wang, Y., Hosey, J., Quintanilla, H., Halton, E., Bernal, Y., Bouhassira, D.C., Arcila, M.E., Gonen, M., Roboz, G.J., Maslak, P., Douer, D., Frattini, M.G., Giralt, S., Sadelain, M. & Brentjens, R. (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine, 6, 224ra25.
21. Di Stasi, A., Tey, S.K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A.G., Grilley, B., Liu, H., Cruz, C.R., Savoldo, B., Gee, A.P., Schindler, J., Krance, R.A., Heslop, H.E., Spencer, D.M., Rooney, C.M. & Brenner, M.K. (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. New England Journal of Medicine, 365, 1673-1683.
22. Eshhar, Z., Waks, T., Gross, G. & Schindler, D.G. (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America, 90, 720-724.
23. Fedorov, V.D., Themeli, M. & Sadelain, M. (2013) PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Science Translational Medicine, 5, 215ra172.
24. Fedorov, V.D., Sadelain, M. & Kloss, C.C. (2014) Novel approaches to enhance the specificity and safety of engineered T cells. Cancer Journal, 20, 160-165.
25. Finney, H.M., Lawson, A.D., Bebbington, C.R. & Weir, A.N. (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. Journal of Immunology, 161, 2791-2797.
26. Finney, H.M., Akbar, A.N. & Lawson, A.D. (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. Journal of Immunology, 172, 104-113.
27. + T cells. Journal of Experimental Medicine, 202, 907-912.
28. Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C.M., Quigley, M.F., Almeida, J.R., Gostick, E., Yu, Z., Carpenito, C., Wang, E., Douek, D.C., Price, D.A., June, C.H., Marincola, F.M., Roederer, M. & Restifo, N.P. (2011) A human memory T cell subset with stem cell-like properties. Nature Medicine, 17, 1290-1297.
29. Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W. & Bujard, H. (1995) Transcriptional activation by tetracyclines in mammalian cells. Science, 268, 1766-1769.
30. Grada, Z., Hegde, M., Byrd, T., Shaffer, D.R., Ghazi, A., Brawley, V.S., Corder, A., Schonfeld, K., Koch, J., Dotti, G., Heslop, H.E., Gottschalk, S., Wels, W.S., Baker, M.L. & Ahmed, N. (2013) TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Molecular Therapy - Nucleic Acids, 2, e105.
31. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., Milone, M.C., Levine, B.L. & June, C.H. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New England Journal of Medicine, 368, 1509-1518.
32. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J.I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L.E., Wissler, M., Prinz, C., Rabbitts, T.H., Le Deist, F., Fischer, A. & Cavazzana-Calvo, M. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415-419.
33. Haso, W., Lee, D.W., Shah, N.N., Stetler-Stevenson, M., Yuan, C.M., Pastan, I.H., Dimitrov, D.S., Morgan, R.A., FitzGerald, D.J., Barrett, D.M., Wayne, A.S., Mackall, C.L. & Orentas, R.J. (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, 121, 1165-1174.
34. Haynes, N.M., Trapani, J.A., Teng, M.W., Jackson, J.T., Cerruti, L., Jane, S.M., Kershaw, M.H., Smyth, M.J. & Darcy, P.K. (2002) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood, 100, 3155-3163.
35. Heczey, A., Liu, D., Tian, G., Courtney, A.N., Wei, J., Marinova, E., Gao, X., Guo, L., Yvon, E., Hicks, J., Liu, H., Dotti, G. & Metelitsa, L.S. (2014) Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood, 124, 2824-2833.
36. Heslop, H.E., Slobod, K.S., Pule, M.A., Hale, G.A., Rousseau, A., Smith, C.A., Bollard, C.M., Liu, H., Wu, M.F., Rochester, R.J., Amrolia, P.J., Hurwitz, J.L., Brenner, M.K. & Rooney, C.M. (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 115, 925-935.
37. + T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood, 117, 808-814.
38. Hombach, A., Sent, D., Schneider, C., Heuser, C., Koch, D., Pohl, C., Seliger, B. & Abken, H. (2001a) T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Research, 61, 1976-1982.
39. Hombach, A., Wieczarkowiecz, A., Marquardt, T., Heuser, C., Usai, L., Pohl, C., Seliger, B. & Abken, H. (2001b) Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. Journal of Immunology, 167, 6123-6131.
40. Hudecek, M., Lupo-Stanghellini, M.T., Kosasih, P.L., Sommermeyer, D., Jensen, M.C., Rader, C. & Riddell, S.R. (2013) Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clinical Cancer Research, 19, 3153-3164.
41. Hudecek, M., Sommermeyer, D., Kosasih, P.L., Silva-Benedict, A., Liu, L., Rader, C., Jensen, M.C. & Riddell, S.R. (2014) The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunology Research. Epub ahead of print. doi:10.1158/2326-6066.CIR-14-0127
42. Imai, C., Mihara, K., Andreansky, M., Nicholson, I.C., Pui, C.H., Geiger, T.L. & Campana, D. (2004) Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia, 18, 676-684.
43. Irving, B.A. & Weiss, A. (1991) The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell, 64, 891-901.
44. James, S.E., Greenberg, P.D., Jensen, M.C., Lin, Y., Wang, J., Till, B.G., Raubitschek, A.A., Forman, S.J. & Press, O.W. (2008) Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. Journal of Immunology, 180, 7028-7038.
45. Jensen, M.C., Popplewell, L., Cooper, L.J., DiGiusto, D., Kalos, M., Ostberg, J.R. & Forman, S.J. (2010) Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biology of Blood and Marrow Transplantation, 16, 1245-1256.
46. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A. & June, C.H. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine, 3, 95ra73.
47. Kershaw, M.H., Westwood, J.A. & Darcy, P.K. (2013) Gene-engineered T cells for cancer therapy. Nature Reviews. Cancer, 13, 525-541.
48. Klingemann, H. (2014) Are natural killer cells superior CAR drivers? Oncoimmunology, 3, e28147.
49. Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nature Biotechnology, 31, 71-75.
50. Kochenderfer, J.N., Feldman, S.A., Zhao, Y., Xu, H., Black, M.A., Morgan, R.A., Wilson, W.H. & Rosenberg, S.A. (2009) Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. Journal of Immunotherapy, 32, 689-702.
51. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., Maric, I., Raffeld, M., Nathan, D.A., Lanier, B.J., Morgan, R.A. & Rosenberg, S.A. (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood, 116, 4099-4102.
52. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., Stetler-Stevenson, M., Phan, G.Q., Hughes, M.S., Sherry, R.M., Yang, J.C., Kammula, U.S., Devillier, L., Carpenter, R., Nathan, D.A., Morgan, R.A., Laurencot, C. & Rosenberg, S.A. (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood, 119, 2709-2720.
53. Kochenderfer, J.N., Dudley, M.E., Carpenter, R.O., Kassim, S.H., Rose, J.J., Telford, W.G., Hakim, F.T., Halverson, D.C., Fowler, D.H., Hardy, N.M., Mato, A.R., Hickstein, D.D., Gea-Banacloche, J.C., Pavletic, S.Z., Sportes, C., Maric, I., Feldman, S.A., Hansen, B.G., Wilder, J.S., Blacklock-Schuver, B., Jena, B., Bishop, M.R., Gress, R.E. & Rosenberg, S.A. (2013) Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood, 122, 4129-4139.
54. Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., Somerville, R.P., Carpenter, R.O., Stetler-Stevenson, M., Yang, J.C., Phan, G.Q., Hughes, M.S., Sherry, R.M., Raffeld, M., Feldman, S., Lu, L., Li, Y.F., Ngo, L.T., Goy, A., Feldman, T., Spaner, D.E., Wang, M.L., Chen, C.C., Kranick, S.M., Nath, A., Nathan, D.A., Morton, K.E., Toomey, M.A. & Rosenberg, S.A. (2014) Chemotherapy-refractory diffuse large b-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology. Epub ahead of print, doi:10.1200/JCO.2014.56.2025
55. Landmeier, S., Altvater, B., Pscherer, S., Meltzer, J., Sebire, N., Pule, M., Vera, J., Hotfilder, M., Juergens, H., Vormoor, J. & Rossig, C. (2010) Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. Leukemia, 24, 1080-1084.
56. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., Steinberg, S.M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S.A., Wayne, A.S. & Mackall, C.L. (2014) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. The Lancet. Epub ahead of print, doi:10.1016/S0140-6736(14)61403-3
57. Maher, J., Brentjens, R.J., Gunset, G., Riviere, I. & Sadelain, M. (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nature Biotechnology, 20, 70-75.
58. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Rheingold, S.R., Shen, A., Teachey, D.T., Levine, B.L., June, C.H., Porter, D.L. & Grupp, S.A. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371, 1507-1517.
59. Milone, M.C., Fish, J.D., Carpenito, C., Carroll, R.G., Binder, G.K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., Campana, D., Riley, J.L., Grupp, S.A. & June, C.H. (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Molecular Therapy, 17, 1453-1464.
60. Philip, B., Kokalaki, E., Mekkaoui, L., Thomas, S., Straathof, K., Flutter, B., Marin, V., Marafioti, T., Chakraverty, R., Linch, D., Quezada, S.A., Peggs, K.S. & Pule, M. (2014) A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood, 124, 1277-1287.
61. Portell, C.A., Wenzell, C.M. & Advani, A.S. (2013) Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clinical Pharmacology: Advances and Applications, 5, 5-11.
62. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. & June, C.H. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New England Journal of Medicine, 365, 725-733.
63. Prosser, M.E., Brown, C.E., Shami, A.F., Forman, S.J. & Jensen, M.C. (2012) Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Molecular Immunology, 51, 263-272.
64. Pule, M., Finney, H. & Lawson, A. (2003) Artificial T-cell receptors. Cytotherapy, 5, 211-226.
65. Pule, M.A., Straathof, K.C., Dotti, G., Heslop, H.E., Rooney, C.M. & Brenner, M.K. (2005) A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Molecular Therapy, 12, 933-941.
66. Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., Huls, M.H., Liu, E., Gee, A.P., Mei, Z., Yvon, E., Weiss, H.L., Liu, H., Rooney, C.M., Heslop, H.E. & Brenner, M.K. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine, 14, 1264-1270.
67. Restifo, N.P., Dudley, M.E. & Rosenberg, S.A. (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews. Immunology, 12, 269-281.
68. Riddell, S.R., Sommermeyer, D., Berger, C., Liu, L.S., Balakrishnan, A., Salter, A., Hudecek, M., Maloney, D.G. & Turtle, C.J. (2014) Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer Journal, 20, 141-144.
69. Rosenberg, S.A., Yang, J.C., Sherry, R.M., Kammula, U.S., Hughes, M.S., Phan, G.Q., Citrin, D.E., Restifo, N.P., Robbins, P.F., Wunderlich, J.R., Morton, K.E., Laurencot, C.M., Steinberg, S.M., White, D.E. & Dudley, M.E. (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research, 17, 4550-4557.
70. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature, 401, 708-712.
71. Savoldo, B., Ramos, C.A., Liu, E., Mims, M.P., Keating, M.J., Carrum, G., Kamble, R.T., Bollard, C.M., Gee, A.P., Mei, Z., Liu, H., Grilley, B., Rooney, C.M., Heslop, H.E., Brenner, M.K. & Dotti, G. (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. Journal of Clinical Investigation, 121, 1822-1826.
72. Scholler, J., Brady, T.L., Binder-Scholl, G., Hwang, W.T., Plesa, G., Hege, K.M., Vogel, A.N., Kalos, M., Riley, J.L., Deeks, S.G., Mitsuyasu, R.T., Bernstein, W.B., Aronson, N.E., Levine, B.L., Bushman, F.D. & June, C.H. (2012) Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Science Translational Medicine, 4, 132ra53.
73. Schwartz, R.H. (2003) T cell anergy. Annual Review of Immunology, 21, 305-334.
74. Straathof, K.C., Pule, M.A., Yotnda, P., Dotti, G., Vanin, E.F., Brenner, M.K., Heslop, H.E., Spencer, D.M. & Rooney, C.M. (2005) An inducible caspase 9 safety switch for T-cell therapy. Blood, 105, 4247-4254.
75. Thomis, D.C., Marktel, S., Bonini, C., Traversari, C., Gilman, M., Bordignon, C. & Clackson, T. (2001) A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood, 97, 1249-1257.
76. Till, B.G., Jensen, M.C., Wang, J., Qian, X., Gopal, A.K., Maloney, D.G., Lindgren, C.G., Lin, Y., Pagel, J.M., Budde, L.E., Raubitschek, A., Forman, S.J., Greenberg, P.D., Riddell, S.R. & Press, O.W. (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood, 119, 3940-3950.
77. Traversari, C., Marktel, S., Magnani, Z., Mangia, P., Russo, V., Ciceri, F., Bonini, C. & Bordignon, C. (2007) The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood, 109, 4708-4715.
78. Wang, X., Chang, W.C., Wong, C.W., Colcher, D., Sherman, M., Ostberg, J.R., Forman, S.J., Riddell, S.R. & Jensen, M.C. (2011) A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood, 118, 1255-1263.
79. Xu, X.J., Zhao, H.Z. & Tang, Y.M. (2013) Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials. Leukemia and Lymphoma, 54, 255-260.
80. Yang, Z.Z. & Ansell, S.M. (2012) The tumor microenvironment in follicular lymphoma. Clinical Advances in Hematology and Oncology, 10, 810-818.